The regulatory-substitution problem
After 2010-2012 regulatory action (FDA banned BPA in infant bottles, EU banned BPA in baby products, Canada listed BPA as toxic), manufacturers replaced BPA with structural analogs — primarily BPS for thermal receipts and food can linings, BPF for some plastic products. The substitutes were not pre-tested for endocrine safety; they were chosen for chemical-property similarity to BPA without the regulatory baggage of the name "BPA."
The Rochester & Bolden 2015 review
Rochester & Bolden in Environmental Health Perspectives (2015) systematically reviewed the literature on bisphenol substitutes and concluded: BPS shows estrogenic activity in cell assays at comparable concentrations to BPA. BPF activity is in the same range. Crucially — BPS and BPF are NOT more rapidly cleared from the body than BPA, and serum half-life is comparable. The substitution effectively replaced one endocrine disruptor with another bearing a different name.
What "BPA-free" actually tells you
"BPA-free" on a product label tells you that one specific chemical (bisphenol A, CAS 80-05-7) is absent. It does NOT tell you that BPS, BPF, or other bisphenol substitutes are absent. It does NOT tell you the product is endocrine-safe. For practical implications, see our complete BPA-free safety review.
Practical exposure reduction
The reliable way to avoid BPA + BPS + BPF + future substitute analogs is to avoid the product categories where they appear: polycarbonate plastic (recycle code #7), epoxy resin-lined food cans, thermal receipt paper, and most types of dental sealants. Choose glass, stainless steel, or ceramic for food contact whenever possible. Fresh or frozen food bypasses can-lining exposure entirely.
Primary source: Rochester JR & Bolden AL 2015 (Environ Health Perspect) — PubMed. Background: Vandenberg et al. 2012 (Endocr Rev) BPA endocrine-disruption review.